Gregg Gilbert
Stock Analyst at Truist Securities
(2.25)
# 2,773
Out of 4,996 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $12.31 | +38.10% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $34.41 | +7.53% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $44.12 | +90.39% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $724.54 | -27.54% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $5.99 | +117.21% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $12.89 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $78.56 | +18.38% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $17.57 | +173.19% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.50 | +1,633.33% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $1.90 | +7,794.74% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $21.45 | +263.64% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $143.50 | -45.64% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $18.34 | -1.85% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $127.00 | +37.80% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $220.61 | -70.08% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $12.31
Upside: +38.10%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $34.41
Upside: +7.53%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $44.12
Upside: +90.39%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $724.54
Upside: -27.54%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $5.99
Upside: +117.21%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $12.89
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $78.56
Upside: +18.38%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $17.57
Upside: +173.19%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.50
Upside: +1,633.33%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $1.90
Upside: +7,794.74%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $21.45
Upside: +263.64%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $143.50
Upside: -45.64%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $18.34
Upside: -1.85%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $127.00
Upside: +37.80%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $220.61
Upside: -70.08%